Phio Pharmaceuticals
PHIO
3 hedge funds and large institutions have $1.19M invested in Phio Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
35% less capital invested
Capital invested by funds: $1.85M → $1.19M (-$655K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$405K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$135K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Broadfin Capital
New York
| $585K | -$405K | -3 | -38% |
|
|
2
Renaissance Technologies
New York
| $336K | +$135K | +1 | +50% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $162K | -$135K | -1 | -50% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $48K | – | – | – |
|
5
Citadel Advisors
Miami,
Florida
| $22K | – | – | – |
|
|
BIT
6
BlackRock Institutional Trust
San Francisco,
California
| $20K | – | – | – |
|
7
UBS Group
Zurich,
Switzerland
| $16K | – | – | – |
|
|
BFA
8
BlackRock Fund Advisors
San Francisco,
California
| $3K | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
WP
11
WealthPLAN Partners
Omaha,
Nebraska
| $2 | – | – | – |
|
PHIO Hedge Fund Activity: Q3 2016 in Review
3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2016, worth a combined $1.19M — down 35% from $1.85M a quarter earlier.
Fund positioning in PHIO was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $135K. The largest seller was Broadfin Capital, cutting an estimated $405K.
- 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $1.19M of Phio Pharmaceuticals stock for Q3 2016, down 35% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q3 2016 and 0 closed out.
- The largest Phio Pharmaceuticals buyer in Q3 2016 was Renaissance Technologies, an estimated $135K added.
- The largest Phio Pharmaceuticals seller in Q3 2016 was Broadfin Capital, an estimated $405K sold.
Based on aggregated 13F filings for Q3 2016.